Navigation Links
ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook
Date:9/21/2007

BUDAPEST, Hungary and SANTA CLARA, California, September 21 /PRNewswire/ -- ChemAxon, a software solutions provider for cheminformatics, and Agilent Technologies Inc. (NYSE: A) today announced an agreement to maintain the integration between the Kalabie Electronic Laboratory Notebook (ELN) and ChemAxon's software suite. Agilent acquired the Kalabie ELN from Klee in June 2007. The contract transitions existing agreements between Klee and ChemAxon to Agilent and ChemAxon.

"We are very pleased to be working with Agilent, as our cheminformatics toolkits are particularly relevant to their current and future strategy," said Ferenc Csizmadia, CEO of ChemAxon.

"Kalabie's unique open design allows easy and effective integration to chemistry cartridge technologies," said Alain Meller, Agilent's ELN director. "The integration with ChemAxon's JChem offers an integrated solution that is seamless in software and services."

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company's 19,000 employees serve customers in more than 110 countries. Agilent had net revenue of $5.0 billion in fiscal year 2006. Information about Agilent is available on the Web at http://www.agilent.com.

About ChemAxon

ChemAxon is a leader in providing cheminformatics software development platforms and applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions and programming interfaces to power modern cheminformatics and chemical communication. For more information please visit http://www.chemaxon.com.

Note to Editors: Further technology, corporate citizenship and executive news is available on the Agilent news site at http://www.agilent.com/go/news.


'/>"/>
SOURCE ChemAxon Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Monitoring transfection efficiency by green fluorescent protein (GFP) detection with the Agilent 2100 bioanalyzer
2. Apoptosis detection by annexin V and active caspase-3 with the Agilent 2100 bioanalyzer
3. Measuring multiple apoptosis parameters with the Agilent 2100 bioanalyzer
4. Flow cytometric analysis of human primary cells using the Agilent 2100 bioanalyzer and on-chip staining
5. Agilent 2100 Bioanalyzer Automated Analysis System
6. Detection of antibody-stained cell surface and intracellular protein targets with the Agilent 2100 bioanalyzer
7. 2100 expert software Powerful software for the analysis of RNA, DNA, proteins, and cells with the Agilent 2100 bioanalyzer
8. siRNA transfection optimization with the Agilent 2100 bioanalyzer
9. Quantitative end-point RT-PCR gene expression measurement using the Agilent 2100 Bioanalyzer and standardized RT-PCR
10. Using the Agilent 2100 bioanalyzer for quality control of protein samples prior to MS-analysis
11. Rapid detection of genomic duplications and deletions using the Agilent 2100 bioanalyzer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... PuraCath Medical, an emerging company ... announced today that it has published the result of its recent research on ... (PDI), the official Journal of the International Society for Peritoneal Dialysis . ...
(Date:2/20/2017)... 20, 2017  Atrius Health and IBM (NYSE: ... agreement to develop a cloud based service designed ... holistic view of the multiple influences on an ... could be designed to support shared decision making ... innovative nonprofit healthcare organization with 875 physicians caring ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) will ... Fla. , The combined scientific sessions offer investigators, clinicians, laboratory technicians, ...
(Date:2/17/2017)... February 17, 2017 According ... by Product (Consumables, Service), Type (Safety, Efficacy, Validation), ... Drug Discovery and Development, Disease-Risk) - Global Forecast ... projected to reach USD 53.34 Billion by 2021 ... a CAGR of 13.8% during the forecast period ...
Breaking Biology Technology:
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
Breaking Biology News(10 mins):